Navigation Links
DURECT Corporation to Participate in Upcoming Healthcare Conferences
Date:11/26/2008

CUPERTINO, Calif., Nov. 26 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that management is scheduled to present at the following upcoming healthcare conferences in New York, NY.

-- 20th Annual Piper Jaffray Health Care Conference on Wednesday, December 3rd at 8:00 a.m. Eastern Time.

-- RBC Capital Markets 2008 Healthcare Conference on Wednesday, December 10th at 12:30 p.m. Eastern Time.

A live audio webcast of the presentations will be available by accessing DURECT's homepage at http://www.durect.com and clicking "Investor Relations." If you are unable to participate during the live webcast, the call will be archived on DURECT's website under Audio Archive in the "Investor Relations" section.

About DURECT Corporation

DURECT is an emerging specialty pharmaceutical company developing innovative drugs for pain and other chronic diseases, with late-stage development programs including REMOXY(R), POSIDUR(TM), ELADUR(TM) and TRANSDUR(TM)-Sufentanil. DURECT's proprietary oral, transdermal and injectable depot delivery technologies enable new indications and superior clinical/commercial attributes such as abuse deterrence, improved convenience, compliance, efficacy and safety for small molecule and biologic drugs. For more information, please visit http://www.durect.com.

NOTE: POSIDUR(TM), SABER(TM), ORADUR(R), TRANSDUR(TM) and ELADUR(TM) are trademarks of DURECT Corporation. Other referenced trademarks belong to their respective owners. REMOXY, POSIDUR, ELADUR and TRANSDUR-Sufentanil are drug candidates under development and have not been approved for commercialization by the US Food and Drug Administration or other health authorities.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO)


'/>"/>
SOURCE DURECT Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. DURECT Corporation to Participate in Upcoming Healthcare Conferences
2. DURECT Corporation Invites You to Join Its Third Quarter 2008 Earnings Conference Call
3. DURECT Announces the IND Submission for a Third Abuse-Resistant Opioid Pain Medication Based on Its ORADUR(TM) Technology
4. DURECT Corporation Invites You to Join Its Second Quarter 2008 Earnings Conference Call
5. DURECT Corporation Presenting at the 2008 UBS Global Generic and Specialty Pharmaceuticals Conference
6. DURECT Corporation Invites You to Join Its First Quarter 2008 Earnings Conference Call
7. DURECT to Participate in Morgan Stanley Global Healthcare Conference
8. DURECT Provides Update on CHRONOGESIC(R) Research Program
9. DURECT to Participate in Cowen Annual Healthcare Conference
10. DURECT to Participate in Susquehanna Financial Healthcare Conference
11. DURECT to Present at BIO CEO Investor Conference 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... D.C. (PRWEB) , ... March 23, 2017 , ... ... (LEAD Coalition) stands with all Americans facing life-altering and fatal diseases in opposition ... budget makes shortsighted decisions that would eviscerate care, services, and hope for the ...
(Date:3/23/2017)... ... , ... The Boulevard is honored to host Shriners and Masons Children’s Day ... in the Main West Entrance of The Boulevard (in front of JCPenney). , ... and each child with a parent or guardian will be photographed for free and ...
(Date:3/23/2017)... ... 23, 2017 , ... “Wounded Woman Be Ye Healed-Passing On A Legacy”: a ... Legacy” is the creation of published author, Desiree M Webb, a registered nurse, minister ... has been happily married to her husband, Paul, for over twenty-nine years. Desiree ...
(Date:3/23/2017)... ... March 23, 2017 , ... “The Trainer”: an electrifying ... author, Scotty, a fiction writer with an active imagination and an enthusiasm for action ... follows the tale of Wild Bill Hart, who sat looking at the thirty-three notches ...
(Date:3/22/2017)... ... March 22, 2017 , ... Cosmetic Town, ... first issue of its companion print magazine. The new magazine, scheduled for release ... to information provided by board-certified doctors from across the country. , According to ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK ) ... a Phase 1 study of MM-310 in solid tumors. ... novel taxane and targets the EphA2 receptor, a protein ... major tumor types, including prostate, ovarian, bladder, gastric, pancreatic ... study is an important step in evaluating MM-310,s safety ...
(Date:3/23/2017)... 23, 2017 /PRNewswire/ - Medicure Inc. ("Medicure" or ... pharmaceutical company, is pleased to announce that its ... from the U.S. Food and Drug Administration (FDA) ... for tetrabenazine tablets in the 12.5 mg and ... a generic equivalent of the branded product Xenazine ...
(Date:3/23/2017)... , March 23, 2017   Casetabs , the ... native mobile app for the iPhone. With this new ... coordination and communication for physician offices, ambulatory surgery centers ... app offers iPhone users even faster, more reliable access ... it even easier to connect care teams so that ...
Breaking Medicine Technology: